LAMP2 and cancer: This activation leads to the upregulation of immunogenic markers, such as calreticulin (CRT), major histocompatibility complex class I (MHC I) molecules, and molecules involved in antigen processing and presentation, including transporter associated with antigen processing 1/2 (Tap1/2) and lysosomal associated membrane protein 2/10 (LAMP2/10), thereby enhancing the immunogenicity of cancer cells [98].